Growth Metrics

Akari Therapeutics (AKTX) Non Operating Investment Income (2026)

Akari Therapeutics (AKTX) has disclosed Non Operating Investment Income for 1 consecutive years, with $230000.0 as the latest value for Q1 2026.

  • Non Operating Investment Income hit $230000.0 in Q1 2026 for Akari Therapeutics.
  • Over the last five years, Non Operating Investment Income for AKTX hit a ceiling of $230000.0 in Q1 2026 and a floor of $230000.0 in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Investment Income (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - 235,807.00
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn -
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - 230,000.00
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn -
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn -
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn -
10 Revolution Medicines 30.42 Bn 30.42 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 230,000.00
Mar 31, 2026 230,000.00